OSE Immunotherapeutics Announces New Research Collaboration with Léon Bérard Cancer Center to Use Artificial Intelligence Technologies to Identify Novel Immuno-Oncology Targets

by NASDAQ Market News March 26, 2019

NASDAQ Market News
Click here to email author

Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) with an IDH1 Mutation in Adult Patients Ineligible for Intensive Chemotherapy

UPS Partners With Matternet To Transport Medical Samples Via Drone Across Hospital System In Raleigh, N.C.

Ads